GLPwatch

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096 · Terminated

Last updated 2026-05-28

This clinical trial compares two treatment approaches in older adults with type 2 diabetes to see which helps more people reach and keep their personalized blood sugar targets without causing dangerous low blood sugar.

Status Terminated Stopped early and will not restart.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 192 people
Who can join Ages 65+ · all sexes
Timeline Started 2014-02 · est. completion 2015-10
Where 34 sites · Austria, Germany, Puerto Rico, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02072096 ↗

Description as written by the study sponsor.

The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.

Treatments tested

Main thing measuredPercentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
SponsorEli Lilly and Company
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02072096 ↗